| First Author | Jayewickreme R | Year | 2021 |
| Journal | Front Immunol | Volume | 12 |
| Pages | 758721 | PubMed ID | 35058919 |
| Mgi Jnum | J:318754 | Mgi Id | MGI:6857061 |
| Doi | 10.3389/fimmu.2021.758721 | Citation | Jayewickreme R, et al. (2021) Endogenous Retroviruses Provide Protection Against Vaginal HSV-2 Disease. Front Immunol 12:758721 |
| abstractText | Endogenous retroviruses (ERVs) are genomic sequences that originated from retroviruses and are present in most eukaryotic genomes. Both beneficial and detrimental functions are attributed to ERVs, but whether ERVs contribute to antiviral immunity is not well understood. Here, we used herpes simplex virus type 2 (HSV-2) infection as a model and found that Toll-like receptor 7 (Tlr7 (-/-)) deficient mice that have high systemic levels of infectious ERVs are protected from intravaginal HSV-2 infection and disease, compared to wildtype C57BL/6 mice. We deleted the endogenous ecotropic murine leukemia virus (Emv2) locus on the Tlr7 (-/-) background (Emv2 (-/-) Tlr7 (-/-)) and found that Emv2 (-/-) Tlr7 (-/-) mice lose protection against HSV-2 infection. Intravaginal application of purified ERVs from Tlr7(-/-) mice prior to HSV-2 infection delays disease in both wildtype and highly susceptible interferon-alpha receptor-deficient (Ifnar1(-) (/-)) mice. However, intravaginal ERV treatment did not protect Emv2(-/-)Tlr7(-/-) mice from HSV-2 disease, suggesting that the protective mechanism mediated by exogenous ERV treatment may differ from that of constitutively and systemically expressed ERVs in Tlr7(-/-) mice. We did not observe enhanced type I interferon (IFN-I) signaling in the vaginal tissues from Tlr7-/- mice, and instead found enrichment in genes associated with extracellular matrix organization. Together, our results revealed that constitutive and/or systemic expression of ERVs protect mice against vaginal HSV-2 infection and delay disease. |
